An effective and safe COVID-19 vaccine is anxiously anticipated by millions of people around the world. A total of 12 vaccines are currently in Phase III (large scale) clinical trials around the globe. In this webinar, two experts in vaccine study design and implementation will present on the current state of clinical research toward a COVID-19 vaccine, review phase II and any new phase III trial data, discuss the end-points of vaccine clinical trials and the threshold(s) for FDA approval of a vaccine, and consider what a vaccine may – and may not – change in the course of the pandemic. Presentations will be followed by discussion and response to audience questions.
- Wafaa El-Sadr, MD, MPH, MPA
ICAP at Columbia University
- Kathleen M. Neuzil, MD, MPH, FIDS
Dr. Neuzil directs the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health (CVD). Throughout her career, she has conducted clinical and epidemiologic studies on vaccine-preventable diseases. At the global non-profit PATH, Dr. Neuzil was instrumental in the introductions of rotavirus, HPV, and Japanese encephalitis vaccines.
- Holly Janes, Ph.D.
Dr. Holly Janes is a senior biostatistician working on the design and analysis of vaccine studies, with a particular expertise in HIV prevention and vaccine science. She also develops and applies statistical methodology for evaluating biomarkers for risk prediction and optimizing treatment decisions.